Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

SHA:688336 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	507.97	459.49	933.26	1,091	1,614	1,778
Short-Term Investments	354.52	863.59	344.19	-	-	50
Trading Asset Securities	863.88	910.54	603.87	1,486	752.05	932.63
Cash & Short-Term Investments	1,726	2,234	1,881	2,577	2,366	2,761
Cash Growth	13.78%	18.73%	-27.00%	8.93%	-14.31%	141.69%
Accounts Receivable	175.47	147.14	133.24	149.35	256.97	102.92
Other Receivables	0.12	0.03	0.2	0.29	0.53	0.5
Receivables	175.59	147.17	133.44	149.65	257.5	103.42
Inventory	240.73	229.6	194.96	227	210.14	225.08
Other Current Assets	896.83	49.64	40.09	32.54	38.09	32.3
Total Current Assets	3,040	2,660	2,250	2,986	2,872	3,122
Property, Plant & Equipment	1,533	1,539	1,562	1,426	1,371	1,287
Long-Term Investments	40.15	1,140	1,020	109.4	122.37	105.59
Goodwill	0.64	0.64	0.64	0.64	0.64	0.64
Other Intangible Assets	220.93	223.96	240.16	195.73	196.55	221.17
Long-Term Deferred Tax Assets	119.64	129.62	145.74	173.43	155.31	103.18
Long-Term Deferred Charges	251.2	228.54	44.44	114.02	97.67	79.48
Other Long-Term Assets	836.8	43.68	42.16	92.76	73.59	35.53
Total Assets	6,042	5,965	5,305	5,098	4,889	4,954
Accounts Payable	32.44	34.96	21.93	15.91	16.27	21.36
Accrued Expenses	40.24	174.93	181.2	56.18	127.71	177.5
Short-Term Debt	50.02	50.02	50.03	150.1	-	-
Current Income Taxes Payable	6.39	1.3	1.3	1.2	0.21	0.21
Current Unearned Revenue	17.44	20.2	16.77	19.55	3.25	15.42
Other Current Liabilities	150.92	35.49	36.91	132.15	68.01	65.83
Total Current Liabilities	297.46	316.91	308.14	375.09	215.45	280.32
Long-Term Unearned Revenue	106.69	111.24	118.33	123.79	134.28	153.11
Total Liabilities	404.14	428.15	426.47	498.88	349.73	433.44
Common Stock	616.79	616.79	616.79	616.79	616.21	616.21
Additional Paid-In Capital	2,313	2,310	2,303	2,309	2,301	2,273
Retained Earnings	2,742	2,639	1,985	1,691	1,641	1,623
Comprehensive Income & Other	-0.16	2.44	-8.71	-10.67	-17.33	-9.68
Total Common Equity	5,671	5,568	4,896	4,606	4,542	4,503
Minority Interest	-33.6	-30.76	-17.58	-6.32	-2.46	17.29
Shareholders' Equity	5,638	5,537	4,879	4,600	4,539	4,520
Total Liabilities & Equity	6,042	5,965	5,305	5,098	4,889	4,954
Total Debt	50.02	50.02	50.03	150.1	-	-
Net Cash (Debt)	1,676	2,184	1,831	2,427	2,366	2,761
Net Cash Growth	14.25%	19.24%	-24.55%	2.59%	-14.31%	141.69%
Net Cash Per Share	2.71	3.53	2.98	3.94	3.93	4.70
Filing Date Shares Outstanding	616.79	616.79	616.79	616.79	616.21	616.21
Total Common Shares Outstanding	616.79	616.79	616.79	616.79	616.21	616.21
Working Capital	2,742	2,343	1,942	2,611	2,656	2,841
Book Value Per Share	9.19	9.03	7.94	7.47	7.37	7.31
Tangible Book Value	5,450	5,343	4,655	4,409	4,344	4,281
Tangible Book Value Per Share	8.84	8.66	7.55	7.15	7.05	6.95
Buildings	-	626.77	626.77	531.48	531.48	516.17
Machinery	-	1,220	1,196	1,043	1,035	1,007
Construction In Progress	-	749.65	687.81	717.11	572.47	434.54

Source: S&P Global Market Intelligence. Standard template. Financial Sources.